Literature DB >> 34273520

Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy.

Faizan Haider Khan1, Basharat Ahmad Bhat2, Bashir Ahmad Sheikh2, Lubna Tariq3, Roshan Padmanabhan4, Jay Prakash Verma5, Amritesh Chandra Shukla6, Afshin Dowlati7, Ata Abbas8.   

Abstract

The lung microbiome plays an essential role in maintaining healthy lung function, including host immune homeostasis. Lung microbial dysbiosis or disruption of the gut-lung axis can contribute to lung carcinogenesis by causing DNA damage, inducing genomic instability, or altering the host's susceptibility to carcinogenic insults. Thus far, most studies have reported the association of microbial composition in lung cancer. Mechanistic studies describing host-microbe interactions in promoting lung carcinogenesis are limited. Considering cancer as a multifaceted disease where epigenetic dysregulation plays a critical role, epigenetic modifying potentials of microbial metabolites and toxins and their roles in lung tumorigenesis are not well studied. The current review explains microbial dysbiosis and epigenetic aberrations in lung cancer and potential therapeutic opportunities.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer treatments; Epigenetic dysregulations; Lung cancer; Lung microbiome; Microbial dysbiosis

Year:  2021        PMID: 34273520     DOI: 10.1016/j.semcancer.2021.07.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  7 in total

1.  Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy.

Authors:  Yu Xi; FangJie Liu; Bo Qiu; Ying Li; XinQiang Xie; JinYu Guo; Lei Wu; TingTing Liang; DaQuan Wang; Juan Wang; Moutong Chen; Liang Xue; Yu Ding; Jumei Zhang; QingPing Wu; Hui Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-01       Impact factor: 6.073

Review 2.  Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review.

Authors:  Giulia Maria Stella; Filippo Scialò; Chandra Bortolotto; Francesco Agustoni; Vincenzo Sanci; Jessica Saddi; Lucio Casali; Angelo Guido Corsico; Andrea Bianco
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

3.  Development of a Prognostic Alternative Splicing Signature Associated With Tumor Microenvironment Immune Profiles in Lung Adenocarcinoma.

Authors:  Guangyao Bao; Tian Li; Xiaojiao Guan; Yao Yao; Jie Liang; Yifan Xiang; Xinwen Zhong
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

4.  Correlation Analysis of the Microbiome and Immune Function in the Lung-Gut Axis of Critically Ill Patients in the ICU.

Authors:  Bin Liu; Ying Yu; Min Zhao; Kun Xiao; Peng Yan; Zhimei Duan; Kaifei Wang; Na Zhao; Jiabao Cao; Jun Wang; Lixin Xie
Journal:  Front Med (Lausanne)       Date:  2022-03-18

5.  Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract.

Authors:  Kai Qian; Yi Deng; William S Krimsky; Yong-Geng Feng; Jun Peng; Yong-Hang Tai; Hao Peng; Li-Hong Jiang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

6.  Altered Lung Microbiome and Metabolome Profile in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease.

Authors:  Runwei Ma; Liming Cheng; Yi Song; Yi Sun; Wenting Gui; Yao Deng; Chao Xie; Min Liu
Journal:  Front Med (Lausanne)       Date:  2022-07-28

7.  Construction and Evaluation of a Preoperative Prediction Model for Lymph Node Metastasis of cIA Lung Adenocarcinoma Using Random Forest.

Authors:  Chuhan Zhang; Shun Xu; Youhong Jiang; Changrui Jiang; Shangxin Li; Zhitong Wang; Yan Dong; Feng Jin; Dan Zhao; Yating Zhao
Journal:  J Oncol       Date:  2022-09-25       Impact factor: 4.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.